Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers

• Published in: Digestion Vol. 97; no. 2; pp. 170 - 176
• Main Authors: Yamasaki, Akira, Yoshio, Toshiyuki, Muramatsu, Yusuke, Horiuchi, Yusuke, Ishiyama, Akiyoshi, Hirasawa, Toshiaki, Tsuchida, Tomohiro, Sasaki, Yutaka, Fujisaki, Junko
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland 01.01.2018
• Subjects: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Drug Substitution - methods; Endoscopic Mucosal Resection - adverse effects; Female; Gastroscopy - adverse effects; Gastroscopy - methods; Humans; Male; Middle Aged; Original Paper; Postoperative Complications - drug therapy; Postoperative Complications - etiology; Proton Pump Inhibitors - therapeutic use; Pyrroles - therapeutic use; Rabeprazole - therapeutic use; Retrospective Studies; Stomach - diagnostic imaging; Stomach - pathology; Stomach - surgery; Stomach Neoplasms - pathology; Stomach Neoplasms - surgery; Stomach Ulcer - diagnostic imaging; Stomach Ulcer - drug therapy; Stomach Ulcer - etiology; Sulfonamides - therapeutic use; Scarring rate; Endoscopic submucosal dissection; Vonoprazan; Rabeprazole
• ISSN: 0012-2823; 1421-9867
• DOI: 10.1159/000485028

Background and Aims: Endoscopic submucosal dissection (ESD) is a well-established minimally invasive treatment for early gastric cancer. To heal ESD-induced ulcers, we commonly prescribe proton pump inhibitors (PPIs). Vonoprazan is our new choice, which is reported to have a stronger and longer acid inhibitory effect than existing PPIs. Here, we aimed to evaluate the efficacy of vonoprazan for healing ESD-induced ulcers compared with rabeprazole. Methods: We reviewed 190 patients who underwent ESD before and after we switched the acid secretion inhibitor from rabeprazole to vonoprazan. We evaluated scarring and reduction rates at 4 weeks after ESD. Results: Scarring rates were not different between vonoprazan and rabeprazole (31.7 vs. 18.9%; p = 0.07). However, for ulcers ≤35 mm, vonoprazan was superior to rabeprazole (42.2 vs. 19.2%; p < 0.05). Reduction rates were superior for vonoprazan compared with rabeprazole (93.0 vs. 90.4%; p < 0.05). In multivariate analysis, vonoprazan was superior to rabeprazole for ulcer scarring (OR 2.21; p < 0.05), and ulcer location in the lower-third of the stomach had higher risk of incomplete scarring (OR 0.37; p < 0.05). Conclusion: Vonoprazan was superior to rabeprazole for healing ESD-induced ulcers.